View Older Stories View More Recent Stories
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Piper Sandler on Amgen (AMGN): 'Repatha Remains a Standout'
-
Cantor Fitzgerald says more options, newer targets will expand obesity market
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Amgen (AMGN) Reports New UPLIZNA Data
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN) as 'ROCA PH3 Horizon Shows Improved Safety'
-
Amgen (AMGN) Starts Late-stage Studies Of Monthly Obesity Drug - Bloomberg, Citing Comments at Conf.
-
Amgen (AMGN) Declares $2.38 Quarterly Dividend; 3% Yield
-
Amgen (AMGN) PT Lowered to $350 at Bernstein Amid MariTide Uncertainty
-
Amgen (AMGN) PT Raised to $329 at Piper Sandler
-
Erste Group Upgrades Amgen (AMGN) to Buy
-
Amgen (AMGN) PT Lowered to $320 at RBC Capital; 'Sound Execution Though Safer Pipeline Play'
-
Amgen (AMGN) PT Lowered to $340 at Cantor Fitzgerald
-
Amgen (AMGN) Tops Q4 EPS by 27c, Beats on Revenue; Offers FY25 EPS Guidance
-
Amgen (AMGN) call put ratio call 1.4 to 1 put into quarter results
-
Amgen (AMGN) call put ratio 2.8 calls to 1 put with a focus on February 360 calls into quarter results
-
Amgen (AMGN) call put ratio 2.1 calls to 1 put into quarter results
-
Piper Sandler on Amgen (AMGN): 'We Envision a Path to Multiple Expansion'
-
Amgen (AMGN) Announces FDA Approval of LUMAKRAS in combination with Vectibix
-
Goldman Sachs Reiterates Buy Rating on Amgen (AMGN)
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Goldman Sachs Reiterates Buy Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Lowered to $324 at RBC Capital Despite Improved Growth Visibility
-
Amgen (AMGN) PT Lowered to $310 at Piper Sandler; 'Well-Positioned To Transcend Key LOE's'
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
Viking Therapeutics (VKTX), Others Gain After Novo Nordisk (NVO) Data Falls Short of Expectations
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Amgen (AMGN) Raises Quarterly Dividend 5.8% to $2.38; 3.5% Yield
-
Amgen (AMGN) Announces $1 Billion Manufacturing Expansion In North Carolina
-
BMO Capital: Five Key BioPharma Catalysts Through Year-End '24
-
Options with decreasing option implied volatility: MSTX MSTU BBIO MSTY AMGN
-
Goldman Issues Monthly Update for US Director's Cut Conviction List
-
Is Trump 2.0 good or bad for healthcare stocks?
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Raised to $352 at Leerink Partners
-
Increasing unusual put option volume: EDR JWN FXY TKO BHC MXEF RCAT URBN NOK ACHR SATS AMGN
-
Oppenheimer Reiterates Outperform Rating on Amgen (AMGN), 'the totality of MariTide's data is still competitive'
-
BTIG Reiterates Viking Therapeutic (VKTX) at Buy, 'continue to see sub-q VK2735 remaining highly competitive'
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Increasing unusual call option volume: KULR RGTI MSTZ NNE QBTS PL DKS SJM VUZI ARQT KODK SIGA SMTC WSM RDW HST AMGN BLBD
-
Morgan Stanley on Amgen (AMGN): 'Initial thoughts on Maritide Ph2 diabesity data'
-
Amgen (AMGN) Falls 8% Following Obesity Data, Rivals Lilly (LLY), Novo Nordisk (NVO) Gain 4%
-
Amgen (AMGN) Announces Robust Weight Loss With Maritide In People Living With Obesity Or Overweight At 52 Weeks In A Phase 2 Study
-
Amgen (AMGN) Appoints Howard Chang as SVP of Research
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Citi Starts Amgen (AMGN) at Neutral
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
